KM Valuation

Q: What is the Fair Price of A083550 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

A083550 (₩2980) is trading above our estimate of [[fair value]] (₩627.54)

Is A083550 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A083550 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A083550 (₩2980) is trading above our estimate of fair value (₩627.54)

Significantly Below Fair Value: A083550 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A083550?

Key metric: As A083550 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for A083550. This is calculated by dividing A083550's market cap by their current revenue.
What is A083550's PS Ratio?
PS Ratio	0.3x
Sales	₩127.12b
Market Cap	₩34.37b

A083550 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.4x
Enterprise Value/EBITDA	-12.9x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does A083550's PS Ratio compare to its peers?

The above table shows the PS ratio for A083550 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	1.9x
A335810 Precision Biosensor	1.9x	n/a	₩33.0b
A450330 HASS	3.8x	n/a	₩61.9b
A142280 Green Cross Medical Science	0.9x	n/a	₩82.1b
A131030 OPTUS Pharmaceutical	1.1x	n/a	₩87.7b
A083550 KM	0.3x	n/a	₩34.4b

Price-To-Sales vs Peers: A083550 is good value based on its Price-To-Sales Ratio (0.3x) compared to the peer average (1.9x).

Price to Sales Ratio vs Industry

How does A083550's PS Ratio compare vs other companies in the KR Medical Equipment Industry?

4 Companies	Price / Sales	Estimated Growth	Market Cap
Industry Avg.	2.1x	23.6%
A083550 KM	0.3x	n/a	US$24.61m
A008490 Suheung	0.2x	6.9%	US$105.73m
A263690 DRGEM	0.6x	n/a	US$44.96m

4 Companies		Estimated Growth	Market Cap
Industry Avg.	2.1x	35.3%
A083550 KM	0.3x	n/a	US$24.61m

No more companies

Price-To-Sales vs Industry: A083550 is good value based on its Price-To-Sales Ratio (0.3x) compared to the KR Medical Equipment industry average (2.1x).

Price to Sales Ratio vs Fair Ratio

What is A083550's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A083550 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.3x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate A083550's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Ray

₩100.3b

RAY Co., Ltd. provides x-ray diagnostic equipment in the dental industry.

A228670

₩6,470.00

-0.3%

-73.4%

Vieworks

₩200.2b

Develops, manufactures, and sells imaging systems and solutions.

A100120

₩21,800.00

6.3%

-19.1%

Boditech Med

₩347.2b

Offers instruments and diagnostic reagents in South Korea and internationally.

A206640

₩15,800.00

0.1%

-10.4%